Abstract 1753P
Background
In up to 30% of gastrointestinal (GI) malignancies, fluoropyrimidines (FP) are associated with severe adverse drug reactions (ADRs). Dihydropyrimidine dehydrogenase (DPYD), is a polymorphic gene involved in FP catabolism. The identification of deleterious variants associated with increased toxicity is recommended before treatment initiation [c.1905+1G>A (*2A); c.1679T>G (*13); c.1129-5923C>G (*IVS10); c.2846A>T (*949) or during treatment in case of ADR [c.2194G>A (*6)]. The estimated prevalence of DPYD deficient genotypes in the European population is <8%. This study aimed to determine the prevalence and implication of systematic DPYD testing in an unselected population with GI tumours.
Methods
The germline DPYD test was conducted on a consecutive series of 1000 pts diagnosed with GI malignancies at our Department between June 2020 and December 2022, candidates for FP for colorectal (CRC 69%), gastroesophageal (GEC 15%), biliopancreatic (BPC 12%), other GI tumours (4%) or double GI malignancy (<1%).
Results
Overall, 819 pts (82%) were DPYD wild type (WT) and 181 (18%) had a deleterious DPYD variant. Among DPYD mutated pts, 134 had CRC (74%), 23 GEC (13%), 17 BPC (9%), 5 other GI tumours (2%) and 1 had CRC and GEC (1%). 184 deleterious variants were observed in 181 pts, the most prevalent was DPYD *6 (N=146 15%) (Table). In 4 pts *6 coexisted with other variants, requiring dose personalization. Of 133 pts enrolled in interventional trials including FP treatment, 24 (18%) reported a deleterious variant: 2A N=1, IVS10 N=2, *6 N=21.
Table: 1753P
DPYD status | N= 1000 | % | FP dosea |
DPYD WT | 819 | 82% | 100% |
DPYD6_c2194G>A homozygosis heterozygosis | 146 * 5 141 | 15% | 70% 85% |
IVS10_1129_5923c>G | 20 | 2% | 50-70% |
DPYD2A_1905+1G>A | 12 | 1% | 50% |
DPYD949_c2846A>T | 5 | <1% | 50% |
DPYD13_c1679T>G | 2 | <1% | 50% |
a recommended dose based on SIF and CPIC guidelines *4 patients presented a double heterozygosis DPYD6 and *2A (N=1), FP dose <50% DPYD6 and c*949 (N=1), FP dose <50% DPYD6 and *IVS10 (N=2), FP dose 50%FP= fluoropyrimidines, WT=wild type
Conclusions
Our large cohort of GI pts revealed a higher prevalence of deleterious DPYD variants compared to previous reports. DPYD*6 was the most frequent genotype and, at a low rate, occurred with other variants requiring major dose adjustments. To prevent severe ADR and to adequately report toxicity and changes in pts' quality of life, our data suggest that DPYD assessment should be mandatory and included in all FP-based clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale.
Funding
Has not received any funding.
Disclosure
C. Cardone: Financial Interests, Personal and Institutional, Advisory Board: Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
1716P - Addressing clinical trial disparities in Spain: A digital solution
Presenter: Max Hardy-Werbin
Session: Poster session 23
1717P - Management of patients during a digital healthcare record system transition: A phase I unit experience
Presenter: Lyra Del Rosario
Session: Poster session 23
1718P - Impact of the economic status of the patient's country of residence on the outcome of oncology clinical trials
Presenter: Saki Nishiyama
Session: Poster session 23
1719P - Decentralized clinical trials: Is there a space in Italy?
Presenter: Celeste Cagnazzo
Session: Poster session 23
1720P - Experience in the provision of oncology services immediately after a major disaster
Presenter: Burak Aktas
Session: Poster session 23
1721P - Self-assessment tool and best-practice sharing to support hospitals in improving the quality of multi-disciplinary teams in lung cancer care
Presenter: Ernest Nadal
Session: Poster session 23
1722P - Factors contributing to differences in evidence compliance rate in cancer treatment among second opinion cases
Presenter: Tomomi Sanomachi
Session: Poster session 23
1723P - Improving access to molecular tumour boards for complex genomic profiles: A healthcare policy from the Netherlands
Presenter: Sahar van Waalwijk van Doorn-Khosrovani
Session: Poster session 23
1724P - Improving access to breast cancer diagnosis and treatment through navigation: Evaluation of a one-year pilot project in Botswana
Presenter: Ariane Migeotte
Session: Poster session 23
1725P - Genetic counselling for cancer in EU member states: Review and foundation for consensus recommendations
Presenter: J. Matt McCrary
Session: Poster session 23